Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer

The vast majority of studies investigating immune checkpoint inhibition (ICI) in patients with breast cancer have focused on triple-negative breast cancer (TNBC). In this study, we compared the tumor immune microenvironment (TIME) between TNBC and hormone receptor-negative HER2-positive breast cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Vos, Hanne, Lambein, Kathleen, Richard, François, Mariën, Bram, Nevelsteen, Ines, Punie, Kevin, Wildiers, Hans, Berben, Lieze, Laenen, Annouschka, Floris, Giuseppe, Desmedt, Christine, Smeets, Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460670/
https://www.ncbi.nlm.nih.gov/pubmed/34556657
http://dx.doi.org/10.1038/s41523-021-00332-7
_version_ 1784571805082583040
author Vos, Hanne
Lambein, Kathleen
Richard, François
Mariën, Bram
Nevelsteen, Ines
Punie, Kevin
Wildiers, Hans
Berben, Lieze
Laenen, Annouschka
Floris, Giuseppe
Desmedt, Christine
Smeets, Ann
author_facet Vos, Hanne
Lambein, Kathleen
Richard, François
Mariën, Bram
Nevelsteen, Ines
Punie, Kevin
Wildiers, Hans
Berben, Lieze
Laenen, Annouschka
Floris, Giuseppe
Desmedt, Christine
Smeets, Ann
author_sort Vos, Hanne
collection PubMed
description The vast majority of studies investigating immune checkpoint inhibition (ICI) in patients with breast cancer have focused on triple-negative breast cancer (TNBC). In this study, we compared the tumor immune microenvironment (TIME) between TNBC and hormone receptor-negative HER2-positive breast cancer based on a selection of immune markers at the protein level in an institutional retrospective series. Additionally, we performed a similar comparison using publicly available transcriptomics data. Altogether, the results show a comparable TIME in both groups, with possible implications for the use of ICI in patients with hormone receptor-negative HER2-positive breast tumors.
format Online
Article
Text
id pubmed-8460670
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-84606702021-10-08 Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer Vos, Hanne Lambein, Kathleen Richard, François Mariën, Bram Nevelsteen, Ines Punie, Kevin Wildiers, Hans Berben, Lieze Laenen, Annouschka Floris, Giuseppe Desmedt, Christine Smeets, Ann NPJ Breast Cancer Brief Communication The vast majority of studies investigating immune checkpoint inhibition (ICI) in patients with breast cancer have focused on triple-negative breast cancer (TNBC). In this study, we compared the tumor immune microenvironment (TIME) between TNBC and hormone receptor-negative HER2-positive breast cancer based on a selection of immune markers at the protein level in an institutional retrospective series. Additionally, we performed a similar comparison using publicly available transcriptomics data. Altogether, the results show a comparable TIME in both groups, with possible implications for the use of ICI in patients with hormone receptor-negative HER2-positive breast tumors. Nature Publishing Group UK 2021-09-23 /pmc/articles/PMC8460670/ /pubmed/34556657 http://dx.doi.org/10.1038/s41523-021-00332-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Brief Communication
Vos, Hanne
Lambein, Kathleen
Richard, François
Mariën, Bram
Nevelsteen, Ines
Punie, Kevin
Wildiers, Hans
Berben, Lieze
Laenen, Annouschka
Floris, Giuseppe
Desmedt, Christine
Smeets, Ann
Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
title Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
title_full Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
title_fullStr Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
title_full_unstemmed Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
title_short Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
title_sort comparison of the tumor immune microenvironment of primary hormone receptor-negative her2-positive and triple negative breast cancer
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460670/
https://www.ncbi.nlm.nih.gov/pubmed/34556657
http://dx.doi.org/10.1038/s41523-021-00332-7
work_keys_str_mv AT voshanne comparisonofthetumorimmunemicroenvironmentofprimaryhormonereceptornegativeher2positiveandtriplenegativebreastcancer
AT lambeinkathleen comparisonofthetumorimmunemicroenvironmentofprimaryhormonereceptornegativeher2positiveandtriplenegativebreastcancer
AT richardfrancois comparisonofthetumorimmunemicroenvironmentofprimaryhormonereceptornegativeher2positiveandtriplenegativebreastcancer
AT marienbram comparisonofthetumorimmunemicroenvironmentofprimaryhormonereceptornegativeher2positiveandtriplenegativebreastcancer
AT nevelsteenines comparisonofthetumorimmunemicroenvironmentofprimaryhormonereceptornegativeher2positiveandtriplenegativebreastcancer
AT puniekevin comparisonofthetumorimmunemicroenvironmentofprimaryhormonereceptornegativeher2positiveandtriplenegativebreastcancer
AT wildiershans comparisonofthetumorimmunemicroenvironmentofprimaryhormonereceptornegativeher2positiveandtriplenegativebreastcancer
AT berbenlieze comparisonofthetumorimmunemicroenvironmentofprimaryhormonereceptornegativeher2positiveandtriplenegativebreastcancer
AT laenenannouschka comparisonofthetumorimmunemicroenvironmentofprimaryhormonereceptornegativeher2positiveandtriplenegativebreastcancer
AT florisgiuseppe comparisonofthetumorimmunemicroenvironmentofprimaryhormonereceptornegativeher2positiveandtriplenegativebreastcancer
AT desmedtchristine comparisonofthetumorimmunemicroenvironmentofprimaryhormonereceptornegativeher2positiveandtriplenegativebreastcancer
AT smeetsann comparisonofthetumorimmunemicroenvironmentofprimaryhormonereceptornegativeher2positiveandtriplenegativebreastcancer

Ejemplares similares